Available evidence suggests that the incidence of leukemia and lymphoma tends to be
higher in highly developed regions of the world and among Whites in the United States …

The classical myeloproliferative neoplasms (MPNs), specifically chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …

Purpose The number of novel oral anticancer agents is increasing, but financial barriers may
limit access. We examined associations between out-of-pocket (OOP) costs and reduced …

Objectives: Specialty drugs often offer medical advances but are frequently subject to high
cost sharing. This is particularly true with Medicare Part D, where after meeting a deductible …

BACKGROUND: Few studies have examined oral anticancer treatment utilization patterns
among Medicare beneficiaries. OBJECTIVE: To assess treatment utilization patterns of …

Objectives: There are very few published chronic myeloid leukaemia (CML) epidemiology
studies in South-East Asia and no representative from Malaysia. Methods: This is a cross …

The myeloproliferative neoplasms, are characterised by overproduction of myeloid cells.
Chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, myelofibrosis …

Outcomes in chronic myeloid leukemia (CML) have been dramatically improved since the
emergence of imatinib and the subsequent generation of tyrosine kinase inhibitors (TKI) in …

Objective The epidemiology of chronic myeloid leukemia is shifting due to the aging global
population and the recent discovery and availability of targeted treatment options. This study …

As our technological capacities improve, genomic testing is increasingly integrating into
patient care. The field of clinical hematology is no exception. Genomic testing carries great …